Next Steps for Patient-Centered Drug Development: Room for More Input, With Limits
This article was originally published in RPM Report
Patient advocates are pushing the Food & Drug Administration to take the next step in the agency’s patient-focused drug development initiative and more directly incorporate the patient experience into regulatory decisions. While that’s a welcomed ask, FDA officials say, it’s not as easy as it looks.
You may also be interested in...
PDUFA V framework to involve patients in the creation of the risk-benefit criteria for various diseases kicks off before the legislation is even enacted.
'Point/Counterpoint' program grew out of Assessment Aid initiative in the Oncology Center of Excellence and will be unveiled at an upcoming ODAC meeting.
US FDA's reorganization of drug reviews splits Keegan's old OHOP division into two.